Quick Answer
Neuphoria Therapeutics Inc. reported Stockholders Equity of $19.00 million for the year ending 2025.
- Neuphoria Therapeutics Inc. showed an increase of +8.6% in Stockholders Equity from 2024 to 2025.
- This data is from Neuphoria Therapeutics Inc.'s annual report (Form 10-K), filed with the SEC on September 29, 2025.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2023: $17.23 million | Q4 2023: $19.50 million | Q1 2024: $17.95 million | Q2 2024: $17.49 million | Q3 2024: $17.07 million | Q4 2024: $13.75 million | Q1 2025: $26.00 million | Q2 2025: $19.00 million | Q3 2025: $12.51 million | Q4 2025: $29.70 million.
- Over the full 4 years of available data (2022 to 2025), Neuphoria Therapeutics Inc.'s Stockholders Equity has declined by 51.6%.
- Historical annual values: Fiscal year 2025: $19.00 million | Fiscal year 2024: $17.49 million | Fiscal year 2023: $22.01 million | Fiscal year 2022: $39.23 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: